A clinical trial to study the effect of G-CSF in sepsis associated immunosupression

Efficacy of Granulocyte colony stimulating factor in sepsis associated immunosupresssion : Open label randomised controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050862

Enrollment

Registered

2023-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems

Interventions

Intervention1: EFfficacy of G-CSF in sepsis associated immunosupression.: G-CSF will be given for 7days, Dose:-4microgram/kg/day s/c. drug will be stopped if TLC30,000/mm3. Subsequent management will

Eligibility

Inclusion criteria

Inclusion criteria: Multi-organ failure more than or equal to 2 systems and persisting for 3days

Exclusion criteria

Exclusion criteria: Macrophage activation syndrome,ferritin >500mg/dl Thrombocytopenia associated Mukti organ failure(TAMOF) Sequential Multiorgan failure Haematological disease (neoplasm,acute leukaemia) ,transplant patients

Design outcomes

Primary

Measure	Time frame
As per picu record @SSH mortality among IPMOF is 63%. Mortality is defined as death within 28days of PICU stay. Reduction in mortality from 63% among IPMOF to 33%Timepoint: 7days,14days and at 28days during hospital stay	—

Secondary

Measure	Time frame
Differences in following parameters between 2 groups at various time points during hospitalisation ,organ failure index IL-6,IL-8 , TNF alpha and nosocomial infectionTimepoint: During admitted in picu	—

Countries

India

Contacts

Public ContactKyatham keerthi

IMS BHU

Kyathamkeerthireddy@gmail.com7702874888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026